尿生存蛋白及膀胱肿瘤抗原在监测膀胱肿瘤复发中的应用比较

Clinical compare bladder tumor antigen with survivin test to the urine in surveillance of recurring bladder cancer patients

目的比较与评价尿生存蛋白(survivin)与膀胱肿瘤抗原(BTAstat)在监测膀胱肿瘤复发中的应用及临床意义。方法在我院膀胱肿瘤住院及门诊确诊或有膀胱肿瘤病史随访患者31例40例次进行尿膀胱肿瘤抗原(BT-Astat)、生存蛋白(survivin)检测,两者均以"+"、"-"判定,依据结果分析两者之间的相关性。并判断两者在早期监测膀胱肿瘤复发的临床意义。结果 survivin与BTAstat对膀胱癌复发的检测具有相关性(P<0.05),可认为两者对膀胱癌复发的检测无明显差别。结论 survivin与BTAstat对膀胱癌复发的检测具有相关性和临床价值;联合应用是可供选择的一个有益的方案。

Objective To evaluate the clinical significance for monitoring recurrence of bladder cancer in the use of BTAstat and survivin.Methods We test 31 bladder cancer inpatients in our hospital and out-patients who are diagnosed as bladder cancer or patients with bladder cancer history by regular visits for BTAstat and survivin,and determine ＂＋＂,＂-＂.According to analysis we know the correlation between the two,and determine the clinical significance for the early monitoring recurrence of bladder cancer in the use of BTAstat and survivin.Results To use McNemanr of spss13.0 to test experimental data,The detection of survivin correl ated with B-actin（P0.05 ）.The detection of survivin does not correlated with BTAstat（P0.05）.Conclusion The test of survivin and BTAstat can improve the detection rate of bladder cancer recurrence and the combined test show better sensibility,which contributes to early detection and treatment.